Clinical Trial

Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a phase 2 trial assessing the efficacy of nivolumab, alone or in combination with relatlimab or ipilimumab in treating patients with locally-advanced unresectable or metastatic basal cell carcinoma.
Protocol Amendment History 12 amendments
This ClinicalTrials.gov record has been amended 12 times since 2018-04-30; most recent amendment 2026-04-27.
Status change: Not Yet Recruiting → Recruiting 2018-11-12
Trial Details
NCT Number NCT03521830
Lead Sponsor Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborators: Bristol-Myers Squibb
Conditions Basal Cell Carcinoma
Enrollment 57 participants
Start Date 2018-11-27
Primary Completion 2027-07 (estimated)
Study Completion 2032-07 (estimated)
Updated on ClinicalTrials.gov 2026-04-29